Related Experiment Video
Updated: Jun 28, 2025

Identification of Mediators of T-cell Receptor Signaling via the Screening of Chemical Inhibitor Libraries
Published on: January 22, 2019
The physiological interactome of TCR-like antibody therapeutics in human tissues
Estelle Marrer-Berger1, Annalisa Nicastri2,3, Angelique Augustin1
1Roche Pharma Research & Early Development, Roche Innovation Center Basel, 4070, Basel, Switzerland.
Abstract:
Selective binding of TCR-like antibodies that target a single tumour-specific peptide antigen presented by human leukocyte antigens (HLA) is the absolute prerequisite for their therapeutic suitability and patient safety. To date, selectivity assessment has been limited to peptide library screening and predictive modeling. We developed an experimental platform to de novo identify interactomes of TCR-like antibodies directly in human tissues using mass spectrometry. As proof of concept, we confirm the target epitope of a MAGE-A4-specific TCR-like antibody. We further determine cross-reactive peptide sequences for ESK1, a TCR-like antibody with known off-target activity, in human liver tissue. We confirm off-target-induced T cell activation and ESK1-mediated liver spheroid killing. Off-target sequences feature an amino acid motif that allows a structural groove-coordination mimicking that of the target peptide, therefore allowing the interaction with the engager molecule. We conclude that our strategy offers an accurate, scalable route for evaluating the non-clinical safety profile of TCR-like antibody therapeutics prior to first-in-human clinical application.
Insights
Developing novel TCR-like antibodies requires rigorous safety testing. This study presents a new mass spectrometry platform to identify antibody interactomes in human tissues, ensuring therapeutic safety and efficacy before clinical trials.
Area of Science:
- Immunology and Cancer Therapeutics
- Proteomics and Mass Spectrometry
Background:
- Therapeutic T-cell receptor (TCR)-like antibodies must selectively bind tumor-specific antigens presented by human leukocyte antigens (HLA) for safety and efficacy.
- Current methods for assessing antibody selectivity, such as peptide library screening and predictive modeling, have limitations.
- Accurate assessment of off-target interactions is crucial for patient safety in TCR-like antibody development.
Purpose of the Study:
- To develop and validate an experimental platform for identifying TCR-like antibody interactomes directly in human tissues.
- To assess the selectivity and potential off-target activities of TCR-like antibodies using mass spectrometry.
- To provide a reliable method for evaluating the non-clinical safety profile of TCR-like antibody therapeutics.
Main Methods:
- Development of a novel experimental platform utilizing mass spectrometry for de novo interactome identification.
- Application of the platform to confirm the target epitope of a MAGE-A4-specific TCR-like antibody.
- Determination of cross-reactive peptide sequences for the ESK1 TCR-like antibody in human liver tissue.
Main Results:
- The platform successfully confirmed the target epitope of a MAGE-A4-specific TCR-like antibody.
- Cross-reactive peptide sequences for the ESK1 antibody were identified in human liver tissue, confirming known off-target activity.
- Off-target interactions were linked to T-cell activation and tissue damage, mediated by a specific amino acid motif.
- The identified motif mimics the target peptide's interaction within the HLA structural groove.
Conclusions:
- The developed mass spectrometry-based platform provides an accurate and scalable method for evaluating TCR-like antibody safety.
- This strategy enables comprehensive assessment of antibody selectivity and off-target interactions in relevant human tissues.
- The findings support the pre-clinical safety evaluation of TCR-like antibody therapeutics prior to clinical application.
More Related Videos
09:53Using X-ray Crystallography, Biophysics, and Functional Assays to Determine the Mechanisms Governing T-cell Receptor Recognition of Cancer Antigens
Published on: February 6, 2017
10:44A Three-dimensional Thymic Culture System to Generate Murine Induced Pluripotent Stem Cell-derived Tumor Antigen-specific Thymic Emigrants
Published on: August 9, 2019
Related Concept Videos
Diversity of Antigen Receptors
Before encountering any antigen, lymphocytes express these receptors. On B cells, the antigen receptor is a membrane-bound antibody molecule called BCR; on T cells, it is a T cell receptor or TCR. B and T cell receptors are composed of two...
T Cell Activation and Clonal Selection
Naive T cells that have not yet encountered an antigen express two primary CD...